The inhibitory role of specific macrophages in RCC
VISIO PHARM
1/19/21, 11:00 AM
America/Pacific Time UTC -8:00 / -7:00
Description
Only a small subset of patients with clear cell Renal Cell Carcinoma (ccRCC) respond to immunotherapy with checkpoint inhibitors. Research has shown that additional mechanisms of inhibition prevent the majority of patients from successful treatment. Recent studies into the inhibitory role of macrophages portend that these cells are associated with lower survival rate in several different cancer types. In this webinar, Immunologist Prof. Dr. Elfriede Nößner will present her research on specific macrophages in RCC (“ercDCs”) which are associated with poor outcome and their potential as new targets in immune therapy.
Learning Objectives
What is known about the role of macrophages in immuno-oncology in general and in RCC specifically
What are “ercDCs” and how do they interact with T-Cells in RCC?
Which possibilities exist to manipulate the ercDCs?
Previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
What is known about the role of macrophages in immuno-oncology in general and in RCC specifically, What are “ercDCs” and how do they interact with T-Cells in RCC?, Which possibilities exist to manipulate the ercDCs?
Inglês
Speakers
Elfriede Nößner
Link to the Event
Banner to the Event
Register your event here
Already have an account? LOGIN HERE. If You don't have an account you need to create a free account.